Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2011 Jun 29;20(9):1902–1911. doi: 10.1158/1055-9965.EPI-11-0221

Table 2.

Summary of performance of multiplexed markers on Bio-Rad and Millipore

Bio-Rad markers with acceptable performance a Bio-Rad markers with <25% detectability b Millipore markers with acceptable performance Millipore markers with acceptable performance a Millipore markers with < 25% detectability b
A2M
CRP
CTACK
C_PEPTIDE
EOTAXIN
FERRITIN
FGF_BASIC
FIBRINOGEN
GHRELIN
GIP
GLP_1
GLUCAGON
GRO
HAPTOGLOBIN
HGF
IFNG
IL_16
IL_18
IL_1RA
IL_2RA
IL_6
IL_8
IL_9
INSULIN
IP_10
LEPTIN
MCP_1MC
MIF
MIG
MIP_1B
M_CSF
PAI_1
PCT
PDGF_BB
RANTES
RESISTIN
SAA
SAP
SCF
SCGF_B
SDF_1A
TNFA
TRAIL
VEGF
VISFATIN
B_NGF
GM_CSF
IFNA2
IL_12P40
IL_15
IL_1A
IL_2
IL_3
LIF
MCP_3
TNFB
Bio-Rad markers with >20% CV c
B_NGF
GM_CSF
G_CSF
IL_10
IL_12P70
IL_13
IL_15
IL_17
IL_1A
IL_1B
IL_2
IL_4
IL_5
IL_7
LIF
MCP_3
MIP_1A
TNFB
TPA
AMYLIN_TOTAL
BCA_1
CCL19_MIP3B
CCL20_MIP3A
CKINE
CRP
CTACK
CXCL11_I_TAC
CXCL6_GCP2
CXCL9_MIG
C_PEPTIDE
EGF
ENA_78
EOTAXIN
EOTAXIN_2
FGF_BASIC
FIT_3_LIGAND
FRACTALKINE
GIP
GLP_1
GLUCAGON
GRO
G_CSF
IFNA2
IFNG
IL_11
IL_12P40
IL_16
IL_1A
IL_29_IFNG1
IL_33
IL_8
INSULIN
IP_10
LEPTIN
LIF
MCP_1
MCP_2
MCP_3
MCP_4
MDC
MIP_1A
MIP_1B
MIP_1D
PP
PYY
SAA
SAP
SCD30
SCD40L
SCF
SDF_1A
SEGFR
SGP130
SILRII
SIL_1RI
SIL_2RA
SIL_4R
SIL_6R
SRAGE
STNFRI
STNFRII
SVEGFR1
SVEGFR2
SVEGFR3
TARC
TNF-A
TPO
TRAIL
TSLP
VEGF
EOTAXIN_3
GHRELIN
IL_20
IL_21
IL_28A
IL_3
IL_4
IL_5
M_CSF
XCL1_LYMPHO
Millipore markers with >20% CV c
GM_CSF
IL_10
IL_12P70
IL_13
IL_15
IL_17
IL_1B
IL_1RA
IL_2
IL_21
IL_23
IL_28A
IL_3
IL_4
IL_5
IL_6_1
IL_7
IL_9
I_309
M_CSF
TGFA
TNFB
XCL1_LYMPHO
a

Acceptable performance was defined as: 1) being detectable in greater than 25% of the 100 samples on all three specimen types and 2) across-batch CVs of <20% for blinded duplicates placed on at least 2 of the three specimen types.

b

Markers with <25% detectability on at least one of three (serum, heparin plasma, and EDTA plasma) specimen types.

c

Markers with coefficients of variation (CVs) for across-batch duplicates >20% on 2 or more of 3 specimen types. CVs were calculated for 20 blinded duplicate samples for each specimen type that were placed across different batches.